Eli Lilly is presenting new clinical trial and real-world evidence at ObesityWeek 2026, highlighting its expanding cardiometabolic portfolio. Key data includes EloraTZP achieving up to 23.3% weight loss in Phase 2 trials and retatrutide demonstrating significant reductions in sleep apnea and knee pain.
Bullish
🤖 60%
At ObesityWeek 2026 (November 14-17) Lilly presents quantified positive data: EloraTZP Phase 2 weight loss up to 23.3% and A1C reduction up to 2.9% at 48 weeks, retatrutide cutting sleep apnea severity by up to 60.6% and knee osteoarthritis pain by up to 75.8%, and Zepbound cutting adolescent BMI by 21.4%. These strengthen the obesity pipeline beyond Zepbound and support future revenue optionality. However, conference presentations of trial data are largely anticipated and no new approvals or guidance are announced, limiting the immediate price move.
Catalysts
- ▲ EloraTZP Phase 2 oral session November 15, 2026: up to 23.3% weight loss and 2.9% A1C reduction at 48 weeks
- ▲ Retatrutide Phase 3 TRIUMPH-1/-2/-4 results showing up to 60.6% AHI reduction and up to 75.8% knee pain reduction
Risk Factors
- ▼ Retatrutide and EloraTZP are investigational and cannot be legally sold, so revenue impact remains distant
- ▼ Data are being presented at a scientific conference and have not been reviewed by regulators